Financhill
Buy
55

FONR Quote, Financials, Valuation and Earnings

Last price:
$14.01
Seasonality move :
-0.08%
Day range:
$13.33 - $14.13
52-week range:
$12.00 - $18.68
Dividend yield:
0%
P/E ratio:
11.30x
P/S ratio:
0.87x
P/B ratio:
0.52x
Volume:
132.6K
Avg. volume:
27.8K
1-year change:
-7.71%
Market cap:
$89M
Revenue:
$102.9M
EPS (TTM):
$1.25

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
FONR
Fonar
-- -- -- -- --
APDN
Applied DNA Sciences
$1.6M -$1.50 27.47% -98.87% --
OCX
OncoCyte
$283.9K -$0.25 180.72% -33.33% $5.42
PRPH
ProPhase Labs
$5.7M -$0.11 3.99% -50% $13.80
VCYT
Veracyte
$124.3M $0.32 6.44% 332.6% $40.50
XWEL
XWELL
-- -- -- -- --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
FONR
Fonar
$14.13 -- $89M 11.30x $0.00 0% 0.87x
APDN
Applied DNA Sciences
$0.54 -- $3.5M -- $0.00 0% 0.10x
OCX
OncoCyte
$3.37 $5.42 $96.4M -- $0.00 0% 15.28x
PRPH
ProPhase Labs
$0.32 $13.80 $13.3M -- $0.00 0% 1.74x
VCYT
Veracyte
$27.16 $40.50 $2.1B 66.24x $0.00 0% 4.63x
XWEL
XWELL
$0.90 -- $4.7M -- $0.00 0% 0.14x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
FONR
Fonar
-- 1.233 -- 9.69x
APDN
Applied DNA Sciences
-- 5.301 -- 3.97x
OCX
OncoCyte
-- -1.798 -- 3.57x
PRPH
ProPhase Labs
22.08% -4.436 25.51% 0.84x
VCYT
Veracyte
-- 3.551 -- 4.54x
XWEL
XWELL
-- -0.848 -- 1.41x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
OCX
OncoCyte
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M

Fonar vs. Competitors

  • Which has Higher Returns FONR or APDN?

    Applied DNA Sciences has a net margin of 9.23% compared to Fonar's net margin of -336%. Fonar's return on equity of 5.33% beat Applied DNA Sciences's return on equity of -84.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    APDN
    Applied DNA Sciences
    37.71% -$15.35 $10.2M
  • What do Analysts Say About FONR or APDN?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 275584.62%. Given that Applied DNA Sciences has higher upside potential than Fonar, analysts believe Applied DNA Sciences is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is FONR or APDN More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.491%.

  • Which is a Better Dividend Stock FONR or APDN?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or APDN?

    Fonar quarterly revenues are $27.2M, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. Fonar's net income of $2.5M is higher than Applied DNA Sciences's net income of -$3.3M. Notably, Fonar's price-to-earnings ratio is 11.30x while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.87x versus 0.10x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.87x 11.30x $27.2M $2.5M
    APDN
    Applied DNA Sciences
    0.10x -- $983.4K -$3.3M
  • Which has Higher Returns FONR or OCX?

    OncoCyte has a net margin of 9.23% compared to Fonar's net margin of -312.02%. Fonar's return on equity of 5.33% beat OncoCyte's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    OCX
    OncoCyte
    61.97% -$0.26 $10.2M
  • What do Analysts Say About FONR or OCX?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand OncoCyte has an analysts' consensus of $5.42 which suggests that it could grow by 60.73%. Given that OncoCyte has higher upside potential than Fonar, analysts believe OncoCyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    OCX
    OncoCyte
    1 2 0
  • Is FONR or OCX More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison OncoCyte has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.749%.

  • Which is a Better Dividend Stock FONR or OCX?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. OncoCyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. OncoCyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or OCX?

    Fonar quarterly revenues are $27.2M, which are larger than OncoCyte quarterly revenues of $2.1M. Fonar's net income of $2.5M is higher than OncoCyte's net income of -$6.7M. Notably, Fonar's price-to-earnings ratio is 11.30x while OncoCyte's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.87x versus 15.28x for OncoCyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.87x 11.30x $27.2M $2.5M
    OCX
    OncoCyte
    15.28x -- $2.1M -$6.7M
  • Which has Higher Returns FONR or PRPH?

    ProPhase Labs has a net margin of 9.23% compared to Fonar's net margin of -209.38%. Fonar's return on equity of 5.33% beat ProPhase Labs's return on equity of -144.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
  • What do Analysts Say About FONR or PRPH?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 4207.12%. Given that ProPhase Labs has higher upside potential than Fonar, analysts believe ProPhase Labs is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is FONR or PRPH More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.472, suggesting its less volatile than the S&P 500 by 147.175%.

  • Which is a Better Dividend Stock FONR or PRPH?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or PRPH?

    Fonar quarterly revenues are $27.2M, which are larger than ProPhase Labs quarterly revenues of $1.4M. Fonar's net income of $2.5M is lower than ProPhase Labs's net income of $4M. Notably, Fonar's price-to-earnings ratio is 11.30x while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.87x versus 1.74x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.87x 11.30x $27.2M $2.5M
    PRPH
    ProPhase Labs
    1.74x -- $1.4M $4M
  • Which has Higher Returns FONR or VCYT?

    Veracyte has a net margin of 9.23% compared to Fonar's net margin of 6.16%. Fonar's return on equity of 5.33% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About FONR or VCYT?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte has an analysts' consensus of $40.50 which suggests that it could grow by 49.12%. Given that Veracyte has higher upside potential than Fonar, analysts believe Veracyte is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    VCYT
    Veracyte
    7 2 1
  • Is FONR or VCYT More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison Veracyte has a beta of 2.145, suggesting its more volatile than the S&P 500 by 114.466%.

  • Which is a Better Dividend Stock FONR or VCYT?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or VCYT?

    Fonar quarterly revenues are $27.2M, which are smaller than Veracyte quarterly revenues of $114.5M. Fonar's net income of $2.5M is lower than Veracyte's net income of $7M. Notably, Fonar's price-to-earnings ratio is 11.30x while Veracyte's PE ratio is 66.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.87x versus 4.63x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.87x 11.30x $27.2M $2.5M
    VCYT
    Veracyte
    4.63x 66.24x $114.5M $7M
  • Which has Higher Returns FONR or XWEL?

    XWELL has a net margin of 9.23% compared to Fonar's net margin of -67.19%. Fonar's return on equity of 5.33% beat XWELL's return on equity of -153.74%.

    Company Gross Margin Earnings Per Share Invested Capital
    FONR
    Fonar
    44.52% $0.37 $160.3M
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
  • What do Analysts Say About FONR or XWEL?

    Fonar has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL has an analysts' consensus of -- which suggests that it could grow by 678.38%. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    FONR
    Fonar
    0 0 0
    XWEL
    XWELL
    0 0 0
  • Is FONR or XWEL More Risky?

    Fonar has a beta of 1.003, which suggesting that the stock is 0.30600000000001% more volatile than S&P 500. In comparison XWELL has a beta of 1.014, suggesting its more volatile than the S&P 500 by 1.396%.

  • Which is a Better Dividend Stock FONR or XWEL?

    Fonar has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fonar pays -- of its earnings as a dividend. XWELL pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios FONR or XWEL?

    Fonar quarterly revenues are $27.2M, which are larger than XWELL quarterly revenues of $7M. Fonar's net income of $2.5M is higher than XWELL's net income of -$4.7M. Notably, Fonar's price-to-earnings ratio is 11.30x while XWELL's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fonar is 0.87x versus 0.14x for XWELL. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    FONR
    Fonar
    0.87x 11.30x $27.2M $2.5M
    XWEL
    XWELL
    0.14x -- $7M -$4.7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Cisco Stock Forecast: Is It Ready to Surprise Us?
Cisco Stock Forecast: Is It Ready to Surprise Us?

Let’s be real Cisco Systems (NASDAQ: CSCO) hasn’t exactly been…

Where Will Gartner Stock Be in 5 Years?
Where Will Gartner Stock Be in 5 Years?

If you’ve ever wondered what it’s like to invest in…

Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?
Rambus (RMBS) Stock Forecast, Can the Rally Continue in 2025?

Rambus has flown under the radar, but the numbers tell…

Stock Ideas

Buy
65
Is MSFT Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 38x

Buy
65
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
33
Is AAPL Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 32x

Alerts

Buy
60
MRUS alert for May 24

Merus NV [MRUS] is up 32.55% over the past day.

Buy
57
RGC alert for May 24

Regencell Bioscience Holdings [RGC] is up 28.43% over the past day.

Buy
90
OKLO alert for May 24

Oklo [OKLO] is up 23.11% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock